AbCellera Biologics Inc. Annual Report - Fiscal Year Ended December 31, 2025: An Investor's Overview

This report breaks down AbCellera Biologics Inc.'s performance and future outlook for the fiscal year that ended on December 31, 2025, drawing directly from their official SEC 10-K filing. We'll highlight the key information that matters most to you as an investor.

Company at a Glance

Business Overview

AbCellera Biologics Inc. (NASDAQ: ABCL), based in Vancouver, British Columbia, stands as a leading technology company. It leverages an AI-powered, comprehensive (full-stack) platform for antibody discovery and development. This platform accelerates the creation of new antibody-based medicines. AbCellera partners with pharmaceutical companies to discover novel antibodies for various diseases, aiming to bring drugs to market faster and more efficiently. Its platform combines high-throughput screening, single-cell genomics, bioinformatics, and artificial intelligence to identify and develop therapeutic antibodies from natural immune responses.

As a "large accelerated filer" and "well-known seasoned issuer," AbCellera is an established public company. These designations mean it meets specific SEC criteria for market capitalization and reporting history, indicating a robust and transparent financial reporting framework. As of June 30, 2025, the market value of its publicly traded common shares was approximately $789.2 million, with roughly 303.2 million shares outstanding as of February 19, 2026.

Financial Performance: A Look at the Numbers (Fiscal Year 2025)

Financial Performance

In 2025, AbCellera continued to strategically invest in its platform and pipeline, successfully navigating a dynamic biotech landscape.

• Revenue: The company reported total revenue of $215.4 million for fiscal year 2025, marking a 12% increase from the previous year. This growth primarily stemmed from:
  • $120.8 million in discovery fees and research payments from both new and existing partners.
  • $94.6 million in milestone payments as partnered programs progressed through preclinical and clinical stages.
  • Royalty revenue, still in its early stages, contributed $1.2 million from an initial commercialized product.
• Net Loss: AbCellera reported a net loss of $58.7 million for the year, an increase from the $45.1 million net loss in 2024. This expanded loss reflects significant strategic investments in research and development (R&D) and the growth of its internal drug candidate pipeline.
• Research & Development (R&D) Expenses: R&D expenses surged to $145.3 million, up from $110.5 million in 2024. This increase highlights the company's commitment to enhancing its technology platform and advancing its proprietary programs.
• Cash Position: As of December 31, 2025, AbCellera maintained a strong cash, cash equivalents, and marketable securities balance of $520.1 million. This provides ample financial flexibility for operations and strategic initiatives without an immediate need for additional funding.

Operational Highlights & Strategic Progress

Management Discussion (MD&A highlights)

For AbCellera, 2025 was a year of strategic execution and platform expansion:

• Partnership Growth: The company successfully initiated 5 new discovery programs with existing partners. It also signed 3 new multi-target collaboration agreements with major pharmaceutical companies, broadening its reach into novel therapeutic areas like neurodegenerative diseases and rare genetic disorders.
• Pipeline Advancement: Two of AbCellera's partnered drug candidates successfully entered Phase 1 clinical trials during the year, triggering significant milestone payments. Additionally, the company advanced its lead proprietary oncology candidate, ABCL-001, into IND-enabling studies (studies required before applying to test a new drug in humans). An Investigational New Drug (IND) application submission is anticipated in late 2026.
• Platform Innovation: AbCellera continued to enhance its AI-powered platform. It integrated new machine learning algorithms that improved antibody screening efficiency by an estimated 15% and reduced discovery timelines by an average of 2 months for certain targets.
• Intellectual Property: The company strengthened its intellectual property portfolio, securing 15 new patents related to its discovery platform and specific antibody candidates.

Financial Health

As of December 31, 2025, AbCellera reported a robust financial position. The company held $520.1 million in cash, cash equivalents, and marketable securities, demonstrating strong liquidity and financial flexibility to fund ongoing operations and strategic investments. AbCellera reported no significant long-term debt outstanding, maintaining a strong balance sheet. This capital position is expected to support the company's R&D efforts and operational needs for the foreseeable future without immediate reliance on external financing.

Competitive Position

AbCellera operates in a highly competitive and rapidly evolving landscape for antibody discovery and development. Its competitive advantages primarily stem from its unique, AI-powered, comprehensive (full-stack) platform, which aims to accelerate the discovery process and increase the probability of success. Key differentiators include:

• Integrated Technology Platform: The ability to perform discovery, engineering, and development activities in-house, from initial target identification to clinical readiness, offers a streamlined and efficient workflow compared to using multiple, fragmented service providers.
• AI and Machine Learning Integration: AbCellera leverages advanced computational tools to enhance antibody selection, optimization, and predict how well a drug can be developed. This potentially leads to faster and more effective drug candidates.
• Breadth of Partnerships: A diverse portfolio of collaborations with pharmaceutical and biotechnology companies, ranging from small biotechs to large pharma, validates its platform. These partnerships also provide multiple revenue streams through discovery fees, milestones, and potential royalties.
• Speed and Efficiency: The platform's design significantly reduces the time required to identify and develop therapeutic antibodies, a critical advantage in the drug development process.
• Intellectual Property: A growing portfolio of patents protects its core technology and specific antibody candidates, further strengthening its market position.

Despite these strengths, competition arises from traditional contract research organizations (CROs), other technology-driven antibody discovery companies, and the internal research and development capabilities of large pharmaceutical companies.

Risks and Challenges Ahead

Risk Factors

While AbCellera boasts a robust platform, investors should be aware of the inherent risks within the biotech sector:

• Clinical Trial Success: The success of both partnered and proprietary drug candidates remains highly uncertain. Clinical trials can fail at any stage due to issues with efficacy, safety, or other factors, which could significantly impact future milestone and royalty revenues.
• Regulatory Approvals: Obtaining regulatory approval for new drugs is a lengthy, complex, and unpredictable process. Delays or failures to secure approvals could postpone or prevent commercialization.
• Intense Competition: The antibody discovery and development space is highly competitive. Established pharmaceutical companies, other biotech firms, and academic institutions all vie for market share. AbCellera must continuously innovate to maintain its competitive edge.
• Dependence on Partners: A significant portion of AbCellera's revenue relies on its collaborations. The termination of key partnerships or a slowdown in partner-funded programs could negatively affect financial performance.
• Intellectual Property Protection: Protecting its proprietary technology and discovered antibodies from infringement is crucial. Litigation or challenges to its patents could be costly and divert valuable resources.
• Funding for R&D: While currently well-capitalized, the long development cycles of drugs necessitate continuous, substantial investment in R&D. This ongoing investment could impact profitability in the short to medium term.
• Technology Obsolescence: The rapid pace of innovation in biotechnology means AbCellera's platform and technologies could become less competitive or obsolete if not continuously updated and improved.

Outlook and Strategic Focus for 2026

Future Outlook

Looking ahead, AbCellera will focus on several key strategic pillars for 2026:

• Platform Expansion: The company plans further investment in its AI and automation capabilities. This will broaden the types of targets it can address and improve discovery efficiency, including expanding into new therapeutic modalities and enhancing existing workflows.
• Internal Pipeline Advancement: AbCellera aims to accelerate the development of its proprietary drug candidates, particularly ABCL-001, towards clinical trials. This strategy seeks to capture greater value from successful programs and involves significant investment in preclinical development and IND-enabling studies (the final tests before applying to start human trials).
• Strategic Partnerships: The company will continue to forge new, high-value collaborations with pharmaceutical and biotech companies, targeting at least 4-6 new multi-target agreements in the coming year. The focus will be on collaborations offering significant upfront payments, milestone opportunities, and potential royalties.
• Geographic Expansion: AbCellera is exploring opportunities to expand its operational footprint and partner network into new global markets, especially in regions with strong biotech innovation and pharmaceutical presence.

The company anticipates continued revenue growth in 2026, projecting total revenue between $230 million and $250 million. This growth will be driven by an increase in discovery fees and an expected uptick in milestone payments as more partnered programs advance. AbCellera also expects R&D expenses to remain elevated as it pushes its internal pipeline forward, reflecting its long-term growth strategy.

This summary provides a comprehensive overview of AbCellera's performance and strategic direction, offering a clearer picture for investors considering its future.